APO Research, Inc.

APO RESEARCH · REPORT

Durvalumab

Selected research

Industry Growth & Trends

Global Durvalumab Industry Growth and Trends Forecast to 2032

Market perspective

The global Durvalumab market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Durvalumab is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Durvalumab is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Durvalumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Durvalumab include Medimmune (AstraZeneca). among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Durvalumab market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Durvalumab market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Durvalumab market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Durvalumab.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Durvalumab market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Durvalumab Market by Company

Medimmune (AstraZeneca)

Durvalumab Segment by Type

2.4mL Injection

10mL Injection

Durvalumab Segment by Application

Locally Advanced Urothelial Carcinoma

Metastatic Urothelial Carcinoma

Others

Durvalumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Durvalumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Durvalumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Durvalumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Durvalumab manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Durvalumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 2.4mL Injection Table 2. Major Company of 10mL Injection Table 3. Global Durvalumab Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Durvalumab Sales by Type (2021-2026) & (k units) Table 5. Global Durvalumab Sales Market Share in Volume by Type (2021-2026) Table 6. Global Durvalumab Sales by Type (2021-2026) & (US$ Million) Table 7. Global Durvalumab Sales Market Share in Value by Type (2021-2026) Table 8. Global Durvalumab Price by Type (2021-2026) & (US$/unit) Table 9. Global Durvalumab Sales by Type (2027-2032) & (k units) Table 10. Global Durvalumab Sales Market Share in Volume by Type (2027-2032) Table 11. Global Durvalumab Sales by Type (2027-2032) & (US$ Million) Table 12. Global Durvalumab Sales Market Share in Value by Type (2027-2032) Table 13. Global Durvalumab Price by Type (2027-2032) & (US$/unit) Table 14. North America Durvalumab Sales by Type (2021-2026) & (k units) Table 15. North America Durvalumab Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Durvalumab Sales by Type (2021-2026) & (k units) Table 17. Europe Durvalumab Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Durvalumab Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Durvalumab Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Durvalumab Sales by Type (2021-2026) & (k units) Table 21. Latin America Durvalumab Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Durvalumab Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Durvalumab Sales by Type (2021-2026) & (US$ Million) Table 24. Durvalumab Industry Trends Table 25. Durvalumab Industry Drivers Table 26. Durvalumab Industry Opportunities and Challenges Table 27. Durvalumab Industry Restraints Table 28. Global Durvalumab Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Durvalumab Revenue Market Share by Company (2021-2026) Table 30. Global Durvalumab Sales by Company (2021-2026) & (k units) Table 31. Global Durvalumab Sales Share by Company (2021-2026) Table 32. Global Durvalumab Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Durvalumab Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Durvalumab Major Company Production Sites and Headquarters Table 35. Global Durvalumab Company, Product Type & Application Table 36. Global Durvalumab Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Durvalumab by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Durvalumab Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Durvalumab Sales by Region (2021-2026) & (k units) Table 41. Global Durvalumab Sales Market Share in Volume by Region (2021-2026) Table 42. Global Durvalumab Sales by Region (2021-2026) & (US$ Million) Table 43. Global Durvalumab Sales Market Share in Value by Region (2021-2026) Table 44. Global Durvalumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Durvalumab Sales by Region (2027-2032) & (k units) Table 46. Global Durvalumab Sales Market Share in Volume by Region (2027-2032) Table 47. Global Durvalumab Sales by Region (2027-2032) & (US$ Million) Table 48. Global Durvalumab Sales Market Share in Value by Region (2027-2032) Table 49. Global Durvalumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Durvalumab Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Durvalumab Sales by Application (2021-2026) & (k units) Table 52. Global Durvalumab Sales Market Share in Volume by Application (2021-2026) Table 53. Global Durvalumab Sales by Application (2021-2026) & (US$ Million) Table 54. Global Durvalumab Sales Market Share in Value by Application (2021-2026) Table 55. Global Durvalumab Price by Application (2021-2026) & (US$/unit) Table 56. Global Durvalumab Sales by Application (2027-2032) & (k units) Table 57. Global Durvalumab Sales Market Share in Volume by Application (2027-2032) Table 58. Global Durvalumab Sales by Application (2027-2032) & (US$ Million) Table 59. Global Durvalumab Sales Market Share in Value by Application (2027-2032) Table 60. Global Durvalumab Price by Application (2027-2032) & (US$/unit) Table 61. North America Durvalumab Sales by Application (2021-2026) & (k units) Table 62. North America Durvalumab Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Durvalumab Sales by Application (2021-2026) & (k units) Table 64. Europe Durvalumab Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Durvalumab Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Durvalumab Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Durvalumab Sales by Application (2021-2026) & (k units) Table 68. Latin America Durvalumab Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Durvalumab Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Durvalumab Sales by Application (2021-2026) & (US$ Million) Table 71. Medimmune (AstraZeneca) Company Information Table 72. Medimmune (AstraZeneca) Business Overview Table 73. Medimmune (AstraZeneca) Durvalumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Medimmune (AstraZeneca) Durvalumab Product Portfolio Table 75. Medimmune (AstraZeneca) Recent Development Table 76. North America Durvalumab Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 77. North America Durvalumab Sales by Country (2021-2026) & (k units) Table 78. North America Durvalumab Sales Market Share by Country (2021-2026) Table 79. North America Durvalumab Sales Forecast by Country (2027-2032) & (k units) Table 80. North America Durvalumab Sales Market Share Forecast by Country (2027-2032) Table 81. North America Durvalumab Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 82. North America Durvalumab Market Size by Country (2021-2026) & (US$ Million) Table 83. North America Durvalumab Market Share by Country (2021-2026) Table 84. North America Durvalumab Market Size Forecast by Country (2027-2032) & (US$ Million) Table 85. North America Durvalumab Market Share Forecast by Country (2027-2032) Table 86. Europe Durvalumab Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 87. Europe Durvalumab Sales by Country (2021-2026) & (k units) Table 88. Europe Durvalumab Sales Market Share by Country (2021-2026) Table 89. Europe Durvalumab Sales Forecast by Country (2027-2032) & (k units) Table 90. Europe Durvalumab Sales Market Share Forecast by Country (2027-2032) Table 91. Europe Durvalumab Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 92. Europe Durvalumab Market Size by Country (2021-2026) & (US$ Million) Table 93. Europe Durvalumab Market Share by Country (2021-2026) Table 94. Europe Durvalumab Market Size Forecast by Country (2027-2032) & (US$ Million) Table 95. Europe Durvalumab Market Share Forecast by Country (2027-2032) Table 96. Asia-Pacific Durvalumab Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 97. Asia-Pacific Durvalumab Sales by Country (2021-2026) & (k units) Table 98. Asia-Pacific Durvalumab Sales Market Share by Country (2021-2026) Table 99. Asia-Pacific Durvalumab Sales Forecast by Country (2027-2032) & (k units) Table 100. Asia-Pacific Durvalumab Sales Market Share Forecast by Country (2027-2032) Table 101. Asia-Pacific Durvalumab Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 102. Asia-Pacific Durvalumab Market Size by Country (2021-2026) & (US$ Million) Table 103. Asia-Pacific Durvalumab Market Share by Country (2021-2026) Table 104. Asia-Pacific Durvalumab Market Size Forecast by Country (2027-2032) & (US$ Million) Table 105. Asia-Pacific Durvalumab Market Share Forecast by Country (2027-2032) Table 106. Latin America Durvalumab Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 107. Latin America Durvalumab Sales by Country (2021-2026) & (k units) Table 108. Latin America Durvalumab Sales Market Share by Country (2021-2026) Table 109. Latin America Durvalumab Sales Forecast by Country (2027-2032) & (k units) Table 110. Latin America Durvalumab Sales Market Share Forecast by Country (2027-2032) Table 111. Latin America Durvalumab Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 112. Latin America Durvalumab Market Size by Country (2021-2026) & (US$ Million) Table 113. Latin America Durvalumab Market Share by Country (2021-2026) Table 114. Latin America Durvalumab Market Size Forecast by Country (2027-2032) & (US$ Million) Table 115. Latin America Durvalumab Market Share Forecast by Country (2027-2032) Table 116. Middle East and Africa Durvalumab Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 117. Middle East and Africa Durvalumab Sales by Country (2021-2026) & (k units) Table 118. Middle East and Africa Durvalumab Sales Market Share by Country (2021-2026) Table 119. Middle East and Africa Durvalumab Sales Forecast by Country (2027-2032) & (k units) Table 120. Middle East and Africa Durvalumab Sales Market Share Forecast by Country (2027-2032) Table 121. Middle East and Africa Durvalumab Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. Middle East and Africa Durvalumab Market Size by Country (2021-2026) & (US$ Million) Table 123. Middle East and Africa Durvalumab Market Share by Country (2021-2026) Table 124. Middle East and Africa Durvalumab Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. Middle East and Africa Durvalumab Market Share Forecast by Country (2027-2032) Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Durvalumab Distributors List Table 129. Durvalumab Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Durvalumab Image Figure 2. Global Durvalumab Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Durvalumab Market Size (2021-2032) & (US$ Million) Figure 4. Global Durvalumab Sales (2021-2032) & (k units) Figure 5. 2.4mL Injection Image Figure 6. Global 2.4mL Injection Sales YoY Growth (2021-2032) & (k units) Figure 7. 10mL Injection Image Figure 8. Global 10mL Injection Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Durvalumab Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Durvalumab Market Share by Type 2025 VS 2032 Figure 11. North America Durvalumab Sales Market Share in Volume by Type in 2025 Figure 12. North America Durvalumab Sales Market Share in Value by Type in 2025 Figure 13. Europe Durvalumab Sales Market Share in Volume by Type in 2025 Figure 14. Europe Durvalumab Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Durvalumab Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Durvalumab Sales Market Share in Value by Type in 2025 Figure 17. Latin America Durvalumab Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Durvalumab Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Durvalumab Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Durvalumab Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Durvalumab Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Locally Advanced Urothelial Carcinoma Image Figure 24. Global Locally Advanced Urothelial Carcinoma Sales YoY Growth (2021-2032) & (k units) Figure 25. Metastatic Urothelial Carcinoma Image Figure 26. Global Metastatic Urothelial Carcinoma Sales YoY Growth (2021-2032) & (k units) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 29. Global Durvalumab Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Durvalumab Market Share by Application 2025 VS 2032 Figure 31. North America Durvalumab Sales Market Share in Volume by Application in 2025 Figure 32. North America Durvalumab Sales Market Share in Value by Application in 2025 Figure 33. Europe Durvalumab Sales Market Share in Volume by Application in 2025 Figure 34. Europe Durvalumab Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Durvalumab Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Durvalumab Sales Market Share in Value by Application in 2025 Figure 37. Latin America Durvalumab Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Durvalumab Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Durvalumab Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Durvalumab Sales Market Share in Value by Application in 2025 Figure 41. North America Durvalumab Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 42. North America Durvalumab Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Durvalumab Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Durvalumab Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Durvalumab Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. Europe Durvalumab Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Durvalumab Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Durvalumab Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Durvalumab Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Asia-Pacific Durvalumab Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Durvalumab Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Durvalumab Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Durvalumab Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Latin America Durvalumab Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Durvalumab Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Durvalumab Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Durvalumab Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Middle East and Africa Durvalumab Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Durvalumab Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Durvalumab Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Durvalumab Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Durvalumab Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • 2.4mL Injection
  • 10mL Injection
Applications
  • Locally Advanced Urothelial Carcinoma
  • Metastatic Urothelial Carcinoma
  • Others
Companies covered
  • Medimmune (AstraZeneca)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Durvalumab Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Durvalumab Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Durvalumab Market by Type
  6. 1.3.1 2.4mL Injection
  7. 1.3.2 10mL Injection
  8. 1.4 Global Durvalumab Market Size by Type
  9. 1.4.1 Global Durvalumab Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Durvalumab Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Durvalumab Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Durvalumab Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Durvalumab Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Durvalumab Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Durvalumab Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Durvalumab Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Durvalumab Industry Trends
  2. 2.2 Durvalumab Industry Drivers
  3. 2.3 Durvalumab Industry Opportunities and Challenges
  4. 2.4 Durvalumab Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Durvalumab Revenue (2021-2026)
  2. 3.2 Global Top Players by Durvalumab Sales (2021-2026)
  3. 3.3 Global Top Players by Durvalumab Price (2021-2026)
  4. 3.4 Global Durvalumab Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Durvalumab Major Company Production Sites & Headquarters
  6. 3.6 Global Durvalumab Company, Product Type & Application
  7. 3.7 Global Durvalumab Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Durvalumab Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Durvalumab Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Durvalumab Tier 1, Tier 2, and Tier 3
4 Durvalumab Regional Status and Outlook
  1. 4.1 Global Durvalumab Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Durvalumab Historic Market Size by Region
  3. 4.2.1 Global Durvalumab Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Durvalumab Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Durvalumab Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Durvalumab Forecasted Market Size by Region
  7. 4.3.1 Global Durvalumab Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Durvalumab Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Durvalumab Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Durvalumab by Application
  1. 5.1 Durvalumab Market by Application
  2. 5.1.1 Locally Advanced Urothelial Carcinoma
  3. 5.1.2 Metastatic Urothelial Carcinoma
  4. 5.1.3 Others
  5. 5.2 Global Durvalumab Market Size by Application
  6. 5.2.1 Global Durvalumab Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Durvalumab Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Durvalumab Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Durvalumab Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Durvalumab Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Durvalumab Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Durvalumab Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Durvalumab Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Medimmune (AstraZeneca)
  2. 6.1.1 Medimmune (AstraZeneca) Company Information
  3. 6.1.2 Medimmune (AstraZeneca) Business Overview
  4. 6.1.3 Medimmune (AstraZeneca) Durvalumab Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Medimmune (AstraZeneca) Durvalumab Product Portfolio
  6. 6.1.5 Medimmune (AstraZeneca) Recent Developments
7 North America by Country
  1. 7.1 North America Durvalumab Sales by Country
  2. 7.1.1 North America Durvalumab Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Durvalumab Sales by Country (2021-2026)
  4. 7.1.3 North America Durvalumab Sales Forecast by Country (2027-2032)
  5. 7.2 North America Durvalumab Market Size by Country
  6. 7.2.1 North America Durvalumab Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Durvalumab Market Size by Country (2021-2026)
  8. 7.2.3 North America Durvalumab Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Durvalumab Sales by Country
  2. 8.1.1 Europe Durvalumab Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Durvalumab Sales by Country (2021-2026)
  4. 8.1.3 Europe Durvalumab Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Durvalumab Market Size by Country
  6. 8.2.1 Europe Durvalumab Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Durvalumab Market Size by Country (2021-2026)
  8. 8.2.3 Europe Durvalumab Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Durvalumab Sales by Country
  2. 9.1.1 Asia-Pacific Durvalumab Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Durvalumab Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Durvalumab Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Durvalumab Market Size by Country
  6. 9.2.1 Asia-Pacific Durvalumab Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Durvalumab Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Durvalumab Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Durvalumab Sales by Country
  2. 10.1.1 South America Durvalumab Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Durvalumab Sales by Country (2021-2026)
  4. 10.1.3 South America Durvalumab Sales Forecast by Country (2027-2032)
  5. 10.2 South America Durvalumab Market Size by Country
  6. 10.2.1 South America Durvalumab Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Durvalumab Market Size by Country (2021-2026)
  8. 10.2.3 South America Durvalumab Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Durvalumab Sales by Country
  2. 11.1.1 Middle East and Africa Durvalumab Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Durvalumab Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Durvalumab Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Durvalumab Market Size by Country
  6. 11.2.1 Middle East and Africa Durvalumab Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Durvalumab Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Durvalumab Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Durvalumab Value Chain Analysis
  2. 12.1.1 Durvalumab Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Durvalumab Production Mode & Process
  7. 12.2 Durvalumab Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Durvalumab Distributors
  10. 12.2.3 Durvalumab Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.